{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:25:15Z","timestamp":1787009115537,"version":"build-2736575974"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,9,1]]},"DOI":"10.1093\/jjco\/hyx084","type":"journal-article","created":{"date-parts":[[2017,5,24]],"date-time":"2017-05-24T07:09:36Z","timestamp":1495609776000},"page":"840-843","source":"Crossref","is-referenced-by-count":25,"title":["A Phase II study of palonosetron, aprepitant, dexamethasone and olanzapine for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in patients with thoracic malignancy"],"prefix":"10.1093","volume":"47","author":[{"given":"Kazuhisa","family":"Nakashima","sequence":"first","affiliation":[{"name":"Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruyasu","family":"Murakami","sequence":"additional","affiliation":[{"name":"Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kouichi","family":"Yokoyama","sequence":"additional","affiliation":[{"name":"Nursing Department, Shizuoka Cancer Center, Shizuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shota","family":"Omori","sequence":"additional","affiliation":[{"name":"Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazushige","family":"Wakuda","sequence":"additional","affiliation":[{"name":"Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Ono","sequence":"additional","affiliation":[{"name":"Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotsugu","family":"Kenmotsu","sequence":"additional","affiliation":[{"name":"Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tateaki","family":"Naito","sequence":"additional","affiliation":[{"name":"Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumie","family":"Nishiyama","sequence":"additional","affiliation":[{"name":"Nursing Department, Shizuoka Cancer Center, Shizuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mami","family":"Kikugawa","sequence":"additional","affiliation":[{"name":"Nursing Department, Shizuoka Cancer Center, Shizuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayo","family":"Kaneko","sequence":"additional","affiliation":[{"name":"Nursing Department, Shizuoka Cancer Center, Shizuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumiko","family":"Iwamoto","sequence":"additional","affiliation":[{"name":"Nursing Department, Shizuoka Cancer Center, Shizuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satomi","family":"Koizumi","sequence":"additional","affiliation":[{"name":"Nursing Department, Shizuoka Cancer Center, Shizuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keita","family":"Mori","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Shizuoka Cancer Center, Shizuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Isobe","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology and Respiratory Medicine, Shimane University Faculty of Medicine, Shimane, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,6,17]]},"reference":[{"key":"key\n\t\t\t\t2018111505155399200_hyx084C1","doi-asserted-by":"crossref","first-page":"4472","DOI":"10.1200\/JCO.2006.05.6382","article-title":"Delayed nausea and vomiting continue to reduce patients\u2019 quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment","volume":"24","author":"Bloechl-Daum","year":"2006","journal-title":"Clin Oncol"},{"key":"key\n\t\t\t\t2018111505155399200_hyx084C2","doi-asserted-by":"crossref","first-page":"v232","DOI":"10.1093\/annonc\/mdq194","article-title":"Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference","volume":"21","author":"Roila","year":"2010","journal-title":"Annal Oncol"},{"key":"key\n\t\t\t\t2018111505155399200_hyx084C3","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1200\/JCO.2015.64.3635","article-title":"Antiemetics: American Society of Clinical Oncology focused guideline update","volume":"34","author":"Hesketh","year":"2016","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2018111505155399200_hyx084C4","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1002\/cncr.11433","article-title":"Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America","volume":"97","author":"Poli-Bigelli","year":"2003","journal-title":"Cancer"},{"key":"key\n\t\t\t\t2018111505155399200_hyx084C5","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1093\/annonc\/mdl019","article-title":"Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment","volume":"17","author":"Schmoll","year":"2006","journal-title":"Ann Oncol"},{"key":"key\n\t\t\t\t2018111505155399200_hyx084C6","doi-asserted-by":"crossref","first-page":"4112","DOI":"10.1200\/JCO.2003.01.095","article-title":"The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin\u2014the Aprepitant Protocol 052 Study Group","volume":"21","author":"Hesketh","year":"2003","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2018111505155399200_hyx084C7","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1093\/annonc\/mdw220","article-title":"Randomized, double-blind, phase III trial of palonosetron versus granisetron in the triplet regimen for preventing chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy: TRIPLE study","volume":"27","author":"Suzuki","year":"2016","journal-title":"Ann Oncol"},{"key":"key\n\t\t\t\t2018111505155399200_hyx084C8","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/1756-9966-28-131","article-title":"Clinical research of olanzapine for prevention of chemotherapy-induced nausea and vomiting","volume":"28","author":"Tan","year":"2009","journal-title":"J Exp Clin Cancer Res"},{"key":"key\n\t\t\t\t2018111505155399200_hyx084C9","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.suponc.2011.05.002","article-title":"Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial","volume":"9","author":"Navari","year":"2011","journal-title":"J Support Oncol"},{"key":"key\n\t\t\t\t2018111505155399200_hyx084C10","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1007\/s00520-012-1710-6","article-title":"The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy","volume":"21","author":"Navari","year":"2013","journal-title":"Support Care Cancer"},{"key":"key\n\t\t\t\t2018111505155399200_hyx084C11","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2512\/jspm.8.127","article-title":"Clinical research of olanzapine for prevention of chemotherapy-induced nausea and vomiting resistant to standard antiemetic treatment for highly emetogenic chemotherapy","volume":"8","author":"Abe","year":"2013","journal-title":"Palliative Care Res"},{"key":"key\n\t\t\t\t2018111505155399200_hyx084C12","volume-title":"Statistical Methods for Rates and Proportions","author":"Fleiss","year":"1981"},{"key":"key\n\t\t\t\t2018111505155399200_hyx084C13","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s00520-015-2829-z","article-title":"Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial","volume":"24","author":"Abe","year":"2016","journal-title":"Support Care Cancer"},{"key":"key\n\t\t\t\t2018111505155399200_hyx084C14","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1515725","article-title":"Olanzapine for the prevention of chemotherapy-induced nausea and vomiting","volume":"375","author":"Navari","year":"2016","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2018111505155399200_hyx084C15","doi-asserted-by":"crossref","first-page":"10111","DOI":"10.1200\/JCO.2016.34.15_suppl.10111","article-title":"A double-blind randomized phase II study of 10 versus 5 mg olanzapine for emesis induced by highly emetogenic chemotherapy with cisplatin","volume":"34","author":"Hashimoto","year":"2016","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2018111505155399200_hyx084C16","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2165\/00003088-199937030-00001","article-title":"Olanzapine. pharmacokinetic and pharmacodynamic profile","volume":"37","author":"Callaghan","year":"1999","journal-title":"Clin Pharmacokinet"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jjco\/article-pdf\/47\/9\/840\/26575229\/hyx084.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,24]],"date-time":"2019-09-24T20:44:06Z","timestamp":1569357846000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/47\/9\/840\/3869511"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,17]]},"references-count":16,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2017,6,17]]},"published-print":{"date-parts":[[2017,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyx084","relation":{},"ISSN":["0368-2811","1465-3621"],"issn-type":[{"value":"0368-2811","type":"print"},{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,9]]},"published":{"date-parts":[[2017,6,17]]}}}